2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Diseases, Hemoglobinopathies, Thalassemia, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

4227 ACCESS-T: A Phase 1 trial of orca-T with dual-agent tacrolimus/ruxolitinib prophylaxis for myeloablative HLA-mismatched allogeneic HCT

Alfonso Molina Jr, MD, MPH, Hrishikesh Srinagesh, MD, MSCR2, Alyssa Kanegai3, Kimi DeNoble4, Sally Arai, MD5, Sushma Bharadwaj, MD6, Saurabh Dahiya, MD7, Mathew J. Frank, MD, PhD8, Hany Elmariah, MD,MS9, Laura Johnston, MD10, Vanessa E Kennedy, MD11, Robert Lowsky, MD12, Everett Meyer, MD, PhD13, Lekha Mikkilineni, MD, MA14, Robert Negrin, MD15, Andrew Rezvani, MD16, Parveen Shiraz, MD17, Judith Anne Shizuru, MD, PhD18, Surbhi Sidana, MD19, Melody Smith, MD,MS20, Hyma Vempaty21, Wen-Kai Weng, MD, PhD22, David Miklos, MD, PhD23, Lori Muffly, MD24
1 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
2 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
3 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
4 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
5 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
6 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
7 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
8 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
9 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
10 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
11 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
12 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
13 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
14 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
15 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
16 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
17 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
18 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
19 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
20 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
21 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
22 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
23 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States
24 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford, California, United States

Background: Use of single-allele HLA-mismatched (7/8) donors at HLA-A, -B, -C, or -DRB1 for allogeneic hematopoietic cell transplantation (HCT) has expanded transplant access for non-White patients but has been historically associated with higher rates of graft-versus-host disease (GVHD), graft failure, and transplant-related mortality (TRM). Post-transplant cyclophosphamide (PTCy) has become standard GVHD prophylaxis in this setting but carries risks of delayed immune reconstitution, infectious complications, and cardiotoxicity.

Allogeneic regulatory T cell immunotherapy with hematopoietic stem and progenitor cells (HSPC) and T cells-vldq (Orca-T), a regulatory T cell-based immunotherapy comprising CD34+ HSPC, regulatory T cells (Treg), and conventional T cells (Tcon), received FDA approval in June 2026 for HLA-matched allogeneic HCT following myeloablative conditioning (MAC), but its use with HLA-mismatched unrelated donors (MMUD) remains investigational. ACCESS-T (NCT06551584) is the first trial specifically aimed at testing the safety and efficacy of Orca-T followed by dual-agent GVHD prophylaxis (tacrolimus plus ruxolitinib [rux]) using MAC with 7/8 MMUD.

Methods: Eligibility includes adults with acute leukemia or myelodysplastic syndromes who are appropriate for MAC HCT, lack available 8/8 donors, but have domestic HLA (7/8) MMUD. Conditioning is with either busulfan-fludarabine-thiotepa (BFT) or TBI-cyclophosphamide (TBI-Cy, 1320 cGy) per provider preference. Orca-T infusion (HSPC and Treg on Day [D]0, Tcon on D+2) is followed by tacrolimus (D+3; goal trough 5-8 ng/mL; taper off by D+180) and short-course rux (D+5 through D+64). Rux is dosed at 5mg twice daily (D+5 through D+34), followed by 5mg daily from D+35 through D+64. Measurable residual disease (MRD) is assessed via bone marrow using flow cytometry and next generation sequencing (NGS) for AML and clonoSEQ® for ALL. The primary endpoint is safety as defined by the proportion of patients free of severe transplant-related adverse events (AEs), non-relapse mortality, graft failure, grade 3–4 acute GVHD, or grade 4–5 opportunistic infection at D+100. Here, we report the baseline characteristics, safety, and early efficacy of the initial safety cohort (n=6).

Results: Four patients had ALL (1 Ph-like B-ALL, 1 Ph+ IKZF1plus B-ALL, 2 ETP-ALL) and two had AML (1 KMT2a rearranged, 1 GATA2/WT1). Median age was 28.7 years (range, 23–37), three (50%) were female, four (66%) identified as Hispanic, one (17%) as non-Hispanic Asian and one (17%) as non-Hispanic White. All patients were in first complete remission, either with full or incomplete count recovery (CR/CRi), and had undetectable MRD prior to HCT. The ALL patients received TBI-Cy and the AML patients received BFT conditioning.

The median (range) HSPC, Treg, Tcon cell doses of Orca-T were 4.35 (3.5-12.7), 1.95 (1.6-2.7) and  4.20 (3.1-5.4) x106 cells/kg, respectively. All patients engrafted, with median (range) time to neutrophil and platelet engraftment of 12 days (10-13) and 15 days (13-15), respectively. No patients have experienced grade 4-5 infections or grade 3-4 acute GVHD. One patient developed grade 2 acute GVHD of the skin and liver, which responded to steroids with resolution. There were no unexpected AEs at least possibly related to Orca-T or ruxolitinib. Grade 3+ AEs included thrombocytopenia (100%), anorexia (83%), oral mucositis (67%), anemia (50%), and febrile neutropenia (50%). One patient developed active tuberculosis (despite negative baseline screening) treated to complete resolution.

With a median follow-up of 129 days (range 94-185), all six patients remain alive without relapse and in ongoing MRD negative remission. Using NGS, median whole blood and CD3 donor chimerism were 99.9% (range, 99–100%) and 99.9% (range, 55–100%) at D+30, respectively and 99.7% (range, 99–99.9%) and 99.9% (range, 81–100%) at D+90, respectively. Thus far, no patients have developed chronic GVHD.

Conclusion: Orca-T has demonstrated superior chronic GVHD-free survival relative to tacrolimus/methotrexate in HLA-matched MAC HCT.  ACCESS-T is designed to determine the safety and initial efficacy of Orca-T using MAC with HLA MMUD. Based on the initial safety cohort, Orca-T plus dual agent GVHD prophylaxis appears promising in this setting, with prompt engraftment and low rates of GVHD. Enrollment is ongoing and additional results will be available for presentation at the Annual Meeting.

Alfonso Molina Jr, MD, MPH: Orca Bio - Consultancy (Includes expert testimony); AROG Pharmaceuticals - Consultancy (Includes expert testimony)